Amarin Corporation plc (the “Company”) has established a
website, https://www.voteamarin.com/, to communicate
with the Company’s shareholders regarding its solicitation of
proxies from shareholders at the Company’s Special General Meeting
of Shareholders to be held on February 28, 2023. Below is an
email to employees issued by the Company on February 21, 2023.
The Company has filed a definitive proxy statement (DEFC14A) and
WHITE proxy card with the U.S. Securities and Exchange Commission
in connection with its solicitation of proxies from shareholders.
Shareholders are strongly encouraged to read such proxy statement
and accompanying WHITE proxy card as they contain important
The following is an employee email issued by the
Subject: Important Message from Karim Mikhail
I know there have been a lot of communications about the proxy
contest over the past few weeks both from me personally and in the
As I said from the outset, this aggressive public back and forth is
typical in a contested election. However, you may have seen that
Sarissa has continued to print factually inaccurate information at
the expense of our Company. I can’t speak for why Sarissa is making
these false statements, but I can speak to the facts about Amarin
and what steps we are taking to hold Sarissa accountable. We have
publicly corrected every misstatement in the strongest terms
possible and have alerted the U.S. Securities and Exchange
Commission (SEC) about Sarissa’s falsehoods and wrongdoings.
When this proxy contest ends, regardless of the outcome, we all
must continue to stay focused on our important work of getting
VASCEPA/VAZKEPA into the hands of our patients who need it — I know
you all are up to the task! The last 18 months at Amarin have been
transformative and exceeded my expectations for where we would be.
A significant transformation like this is not easy and it doesn’t
happen overnight. We have reimagined the Company from our people to
our strategy to our investments, and I could not be prouder of what
we have achieved together.
It’s not just me who recognizes our hard work and what we have
achieved. Our Board of Directors stands firmly behind our team and
has the utmost confidence in Amarin’s future. Our success in
stabilizing our U.S. business, the positive pricing and
reimbursement discussions we are having every day in Europe, and
our regulatory efforts across International reaffirm our unique
product and the importance of Amarin’s mission. We must not let up
on our critical work and continue driving forward toward successful
outcomes, because this will make a difference for patients.
On behalf of the entire Board, thank you for all of your hard work
and your continued commitment to Amarin.
President & Chief Executive Officer
Consistent with company policy, if you receive any inquiries
from members of the media, analysts, or investors, please direct
them to Lisa DeFrancesco or Mark Marmur.
This communication contains forward-looking statements which are
made pursuant to U.S. federal securities law. These forward-looking
statements are not promises or guarantees and involve substantial
risks and uncertainties. A further list and description of these
risks, uncertainties and other risks associated with an investment
in Amarin can be found in Amarin’s filings with the U.S. Securities
and Exchange Commission, including Amarin’s annual report on
Form 10-K for the
full year ended 2021, and Amarin’s quarterly reports on
Form 10-Q for the
quarters ended March 31, 2022, June 30, 2022, and
September 30, 2022, and its other filings. Existing and
prospective investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
they are made. Amarin undertakes no obligation to update or revise
the information contained in its forward-looking statements,
whether as a result of new information, future events or
circumstances or otherwise. Amarin’s forward-looking statements do
not reflect the potential impact of significant transactions the
company may enter into, such as mergers, acquisitions,
dispositions, joint ventures or any material agreements that Amarin
may enter into, amend or terminate.